Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St to open higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Leerink Partners Reiterates Outperform Rating on Repligen (RGEN)
March 4, 2025 9:50 AM ESTLeerink Partners analyst Puneet Souda reiterated an Outperform rating and $200.00 price target on Repligen (NASDAQ: RGEN)
The analyst comments "Bottom Line: This morning, RGEN (OP) announced the acquisition of MASS's (MP) bioprocessing desktop portfolio including REBEL, MAVERICK/MAVEN, and ZipChip (overall ~450 total... More
